Abstract

BackgroundThe effectiveness of TNF-inhibitors (TNFi) in the treatment of rheumatoid arthritis has been demonstrated in many studies [1]. However, little is known on stopping TNFi in patients with stable low...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Late‐Breaking Abstracts
...
Arthritis & Rheumatology | VOL. 66
, et. al. ...
25 Nov 2014
FRI0422 Successful dose reduction of tnf-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity
M Efde ... E Van Der Veer
Annals of the Rheumatic Diseases | VOL. 72
M Efde, et. al.M Efde ... E Van Der Veer
01 Jun 2013
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review
M E Van Muijen ... J M P A Van Den Reek
Drugs | VOL. 81
M E Van Muijen, et. al.M E Van Muijen ... J M P A Van Den Reek
16 Jan 2021
AB0263 Predictive value of a single measurement of the multi-biomarker disease activity (MBDA) score for disease flares within 6 and 12 months in rheumatoid arthritis patients using tumor necrosis factor inhibitors and conventional synthetic dmards
Mvd Laar ... Pmt Klooster
Annals of the Rheumatic Diseases | VOL. 76
Mvd Laar, et. al.Mvd Laar ... Pmt Klooster
01 Jun 2017
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers